Assessing the prospects of various methods to model and modify the tumour microenvironment (TME)
How to increase their efficiency, flexibility and productivity in line with expected future trends in supply and demand
Where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?
What is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?
I-O discovery and development as driven by advances in bioinformatics and other technological innovation
How next-gen biopharma manufacturing solutions will drive improvements in process and product robustness
Cost of goods control and clinical/HTA strategies for market access success